A PYMNTS Company

Canada/US: Valeant shocks with even larger Allergan offer

By  |  June 1, 2014

Valeant Pharmaceuticals surprised the industry late last week when it upped its offer to acquire Allergan, the second such bid increase in a single week.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Canadian company reportedly boosted its offer to $53 billion to acquire the Botox manufacturer. The offer stacks up at $72 a share, increased from last Wednesday’s offer of $58.30 a share.

    In a statement from Valeant, the company said its increased offer is contingent upon Allergan responding promptly to the proposal so the two can launch negotiations.

    Last month Allergan rejected a $46 billion offer from Valeant because it undervalued the company’s worth, Allergan said.

    Full content: USA Today

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.